A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies

Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), has demonstrated greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties tha...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2002-07, Vol.8 (7), p.2142-2148
Hauptverfasser:	PATNAIK, Amita, ROWINSKY, Eric K, ECKHARDT, S. Gail, VILLALONA, Miguel A, HAMMOND, Lisa A, BRITTEN, Carolyn D, SIU, Lillian L, GOETZ, Andrew, FELTON, Sally A, BURTON, Susan, VALONE, Frank H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Butyrates - administration & dosage Butyrates - therapeutic use Cell Differentiation Chemotherapy Drug Administration Schedule Female Humans Male Maximum Tolerated Dose Medical sciences Middle Aged Neoplasms - drug therapy Neoplasms - metabolism Pharmacology. Drug treatments Prodrugs - adverse effects Prodrugs - therapeutic use Safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!